Overview

Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation

Status:
Unknown status

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate safety and prophylaxis effect of micafungin after hematopoietic stem cell transplantation. Micafungin is administered until confirmation of neutrophil engraftment or treatment failure.

Phase:

Phase 4

Details

Lead Sponsor:

Asan Medical Center

Collaborator:

Astellas Pharma Korea, Inc.

Treatments:

Echinocandins
Micafungin